Opinion
Video
The Impact of Comorbidities, Adherence, and Access on mCRPC Treatment Decisions
Author(s):
A panelist discusses how patient comorbidities like diabetes and liver disease influence abiraterone formulation selection, noting that some physicians worry about steroid effects on blood glucose and the importance of monitoring liver function.
Food-Drug Interactions and Absorption Considerations
This segment provides crucial information about the significant impact of food on abiraterone absorption and the clinical implications for patient safety and efficacy. Fatty meals can dramatically increase abiraterone absorption, potentially leading to dangerously elevated drug levels when patients consume the full recommended dose with high-fat foods. This pharmacokinetic interaction explains why the traditional formulation requires strict fasting conditions to ensure predictable and safe drug absorption.
The microformulation technology addresses these absorption variability concerns by maintaining consistent bioavailability regardless of food intake. This advancement eliminates the need for patients to maintain precise fasting windows while taking multiple pills, reducing both the complexity of the dosing regimen and the risk of inadvertent overdosing. The discussion emphasizes how this technological improvement translates into practical benefits for patient management and adherence.
Understanding these food-drug interactions becomes essential for clinicians managing patients on abiraterone therapy, particularly when counseling patients about proper administration techniques. The segment underscores that incorrect dosing due to food interactions can not only reduce therapeutic efficacy but also increase the risk of adverse effects, making patient education about proper drug administration a critical component of successful prostate cancer treatment.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
